PROGNOSTIC-SIGNIFICANCE OF NONFATAL REINFARCTION DURING 3-YEAR FOLLOW-UP - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) PHASE-II CLINICAL-TRIAL

被引:49
|
作者
MUELLER, HS
FORMAN, SA
MENEGUS, MA
COHEN, LS
KNATTERUD, GL
BRAUNWALD, E
机构
[1] MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, BRONX, NY 10467 USA
[2] YALE UNIV, SCH MED, NEW HAVEN, CT USA
[3] HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, BOSTON, MA 02115 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1016/0735-1097(95)00270-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. This study sought to assess the independent contribution of nonfatal reinfarction to the risk of subsequent death in patients with acute myocardial infarction undergoing thrombolytic therapy. Background. A composite of ''unsatisfactory outcomes'' as an end point has increased statistical power and facilitated evaluation of evolving treatment regimens in acute myocardial infarction, The significance of nonfatal reinfarction as a component of a composite end point has not been evaluated in the thrombolytic era. Methods. Event rate of nonfatal reinfarction over 3-year follow-up was evaluated in patients with acute myocardial infarction entered into the Thrombolysis in Myocardial Infarction Phase II trial, The independent risk of nonfatal reinfarction for subsequent death within various time intervals of follow-up was determined. The mortality rate after nonfatal reinfarction was compared with that of a matched control group. Results. During 3 year follow up, 349 of 3,339 patients had a nonfatal reinfarction, Univariate predictors were history (antedating the index event) of angina (p = 0.01), hypertension (p = 0.01), multivessel disease (p = 0.007) and not a current smoker (p = 0.003); the latter was an independent predictor (relative risk [RR] 1.3, 99% confidence interval [CI] 1.0 to 1.8), Forty-three of the 349 patients with a nonfatal reinfarction died: RR for death (VS, patients without a nonfatal reinfarction) was 1.9 (99% CI 1.1 to 3.2) if reinfarction occurred within 42 days of study entry, 6.2 (99% CI 3.0 to 12.9) if reinfarction occurred between 43 and 365 days and 2.9 (99% CI 0.6 to 13.4) if reinfarction occurred between 366 days and 3 years, The cumulative 3-year death rate was 14.1% in patients,vith a nonfatal reinfarction compared with 7.9% (p < 0.01) in a matched control group, Univariate predictors of death after nonfatal reinfarction were age greater than or equal to 65 years (p < 0.001), not low risk category (p = 0.015) and history of heart failure before the index event (p < 0.001), Age greater than or equal to 65 years was the only independent predictor (RR 5.4, 99% CI 2.3 to 12.4). Conclusions. Nonfatal reinfarction is a strong and independent predictor for subsequent death, It represents a powerful component for a composite end point in patients who received thrombolytic therapy after acute myocardial infarction.
引用
收藏
页码:900 / 907
页数:8
相关论文
共 50 条
  • [1] 2-YEAR AND 3-YEAR RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) PHASE-II CLINICAL-TRIAL
    TERRIN, ML
    WILLIAMS, DO
    KLEIMAN, NS
    WILLERSON, J
    MUELLER, HS
    DESVIGNENICKENS, P
    FORMAN, SA
    KNATTERUD, GL
    BRAUNWALD, E
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1993, 22 (07) : 1763 - 1772
  • [2] THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) PHASE-II TRIAL
    NORRIS, RM
    NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (09): : 612 - 612
  • [3] RACE AND PROGNOSIS AFTER MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) PHASE-II TRIAL
    TAYLOR, HA
    CHAITMAN, BR
    ROGERS, WJ
    KERN, MJ
    TERRIN, ML
    AGUIRRE, FV
    SOPKO, G
    MCMAHON, R
    ROSS, RN
    BOVILL, EC
    CIRCULATION, 1993, 88 (04) : 1484 - 1494
  • [4] THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) TRIAL PHASE-II - ADDITIONAL INFORMATION AND PERSPECTIVES
    BAIM, DS
    BRAUNWALD, E
    FEIT, F
    KNATTERUD, GL
    PASSAMANI, ER
    ROBERTSON, TL
    ROGERS, WJ
    SOLOMON, RE
    WILLIAMS, DO
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 15 (05) : 1188 - 1192
  • [5] ONE-YEAR RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION INVESTIGATION (TIMI) PHASE II TRIAL
    WILLIAMS, DO
    BRAUNWALD, E
    KNATTERUD, G
    BABB, J
    BRESNAHAN, J
    GREENBERG, MA
    RAIZNER, A
    WASSERMAN, A
    ROBERTSON, T
    ROSS, R
    THOMPSON, B
    BELL, WR
    SCHERLIS, L
    DODGE, HT
    BROWN, BG
    KENNEDY, JW
    SHEEHAN, FH
    BISSON, B
    BOLSON, E
    ZARET, B
    WACKERS, F
    KAYDEN, DS
    DAVIS, K
    GREEN, R
    MANN, K
    STUMP, D
    COLLEN, D
    BOVILL, E
    TRACY, R
    ROSS, AM
    BREN, GB
    WASSERMAN, AG
    CHAITMAN, BR
    WIENS, RD
    SHAW, L
    HAUEISEN, M
    YOUNIS, LT
    PASSAMANI, ER
    ROBERTSON, TL
    LAN, G
    SOLOMON, R
    SOPKO, G
    ROBERTS, WC
    KALAN, J
    WILLIAMS, DO
    RILEY, R
    WHITE, H
    SHARAF, B
    FEDELE, F
    THOMAS, E
    CIRCULATION, 1992, 85 (02) : 533 - 542
  • [7] INTRACEREBRAL HEMORRHAGE, CEREBRAL INFARCTION, AND SUBDURAL-HEMATOMA AFTER ACUTE MYOCARDIAL-INFARCTION AND THROMBOLYTIC THERAPY IN THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION STUDY - THROMBOLYSIS IN MYOCARDIAL-INFARCTION, PHASE-II, PILOT AND CLINICAL-TRIAL
    GORE, JM
    SLOAN, M
    PRICE, TR
    RANDALL, AMY
    BOVILL, E
    COLLEN, D
    FORMAN, S
    KNATTERUD, GL
    SOPKO, G
    TERRIN, ML
    CIRCULATION, 1991, 83 (02) : 448 - 459
  • [8] 6-MONTH AND 12-MONTH FOLLOW-UP OF THE PHASE-I THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) TRIAL
    DALEN, JE
    GORE, JM
    BRAUNWALD, E
    BORER, J
    GOLDBERG, RJ
    PASSAMANI, ER
    FORMAN, S
    KNATTERUD, G
    AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (04): : 179 - 185
  • [9] HEMORRHAGIC EVENTS DURING THERAPY WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR, HEPARIN, AND ASPIRIN FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI), PHASE-II TRIAL
    BOVILL, EG
    TERRIN, ML
    STUMP, DC
    BERKE, AD
    FREDERICK, M
    COLLEN, D
    FEIT, F
    GORE, JM
    HILLIS, LD
    LAMBREW, CT
    LEIBOFF, R
    MANN, KG
    MARKIS, JE
    PRATT, CM
    SHARKEY, SW
    SOPKO, G
    TRACY, RP
    CHESEBRO, JH
    ANNALS OF INTERNAL MEDICINE, 1991, 115 (04) : 256 - 265